Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 21, Topic 2
In Progress

Status Epilepticus: Clinical Foundations and Management

Lesson Progress
0% Complete
Diagnostic and Classification Criteria in Status Epilepticus

Diagnostic and Classification Criteria in Status Epilepticus

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Learning Objective

  • Apply diagnostic and classification criteria to assess the severity of status epilepticus (SE) and guide immediate management.

Overview: Status epilepticus is a neurologic emergency defined by seizure duration and response to therapy. Early recognition, targeted diagnostics, and prompt classification drive appropriate pharmacologic escalation and improve outcomes.

1. Operational Definitions and Classification

SE definitions hinge on time thresholds and treatment response. Classification into standard, refractory, and super-refractory SE informs urgency and therapy intensity.

Standard SE:

  • Single seizure ≥5 minutes or ≥2 seizures without return to baseline consciousness.
  • Rationale: spontaneous cessation unlikely beyond 5 minutes; early benzodiazepine improves cessation rates.

Refractory SE (RSE):

  • Ongoing seizures after adequate benzodiazepine (e.g., lorazepam 0.1 mg/kg IV) plus a second‐line Antiseizure Medication (ASM) (fosphenytoin 20 mg PE/kg, valproate 20–40 mg/kg, or levetiracetam 60 mg/kg).

Super-Refractory SE (SRSE):

  • SE persisting >24 hours despite continuous anesthetic infusion or recurring on anesthetic wean.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearl

The 5-minute operational threshold balances the need for early intervention against overtreatment of self-limited seizures.

2. Clinical Examination and Differentiation from Mimics

Differentiate true SE from psychogenic seizures and movement disorders via history, exam, and response to therapy.

A. History:

  • Prodrome/aura, witness descriptions, prior epilepsy, ASM adherence, triggers (infection, stroke).

B. Bedside neurologic exam:

  • Focal motor signs (unilateral clonic jerking), eye deviation, automatisms, postictal confusion.

C. Psychogenic Non-Epileptic Seizures (PNES):

  • Asynchronous/arrhythmic movements, preserved awareness, lack of postictal state, normal EEG during events.

D. Hyperkinetic Movement Disorders:

  • Rhythmicity vs arrhythmic, distractible, entrainable limbs, normal EEG.

Case Vignette: A 62-year-old man on the ventilator develops 7 minutes of subtle facial twitching and confusion. Rapid fingerstick glucose is normal; emergent EEG confirms rhythmic epileptiform discharges—initiate benzodiazepine and second-line ASM.

Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl

In suspected PNES or movement disorders, absence of EEG seizures despite dramatic movements should prompt reevaluation before ASM escalation.

3. Emergent Laboratory Evaluation

Identify reversible precipitants and optimize ASM selection through targeted labs performed in parallel with initial therapy.

  • Metabolic panel: sodium, potassium, calcium, magnesium, glucose
  • Renal/hepatic function: creatinine, BUN, AST/ALT, bilirubin
  • Toxicology screen: alcohols, illicit drugs, proconvulsant medications
  • Infection workup: CBC, CRP/ESR, blood cultures, CSF analysis if fever or meningeal signs
  • ASM levels: phenytoin, valproate, carbamazepine in known epileptics
Common Antiseizure Medication (ASM) Levels and Considerations
ASM Therapeutic Range Toxic Level Notes
Phenytoin 10-20 mcg/mL >30 mcg/mL Monitor free level if albumin low; highly protein-bound.
Valproate 50-100 mcg/mL >150 mcg/mL Check ammonia if encephalopathy develops.
Carbamazepine 4-12 mcg/mL >15 mcg/mL Autoinducer; monitor for drug interactions.
Levetiracetam (Not routinely monitored) N/A Dose adjust for renal impairment; generally well-tolerated.
Phenobarbital 15-40 mcg/mL >50 mcg/mL Significant sedation; respiratory depression risk.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearl

Do not delay benzodiazepine administration to await laboratory results—correct reversible causes concurrently.

4. Neuroimaging in SE

Early imaging defines structural etiologies that may alter management.

  • Noncontrast head CT (emergent): rule out hemorrhage, mass effect—perform at bedside if unstable.
  • Brain MRI (DWI/FLAIR): detect ischemia, inflammation, subtle lesions once patient stabilized.
  • Vascular imaging (CTA/MRA): indicated when stroke suspected; perfusion studies for salvageable tissue.

Imaging Algorithm:

Neuroimaging Algorithm in SE

1. Emergent Noncontrast Head CT
(All new-onset SE or unexplained neurologic deterioration)
2. Brain MRI (after stabilization or if CT non-diagnostic)
Figure 1: Neuroimaging Algorithm in Status Epilepticus. This simplified algorithm highlights the typical sequence of imaging studies.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl

While CT is rapid and widely available, MRI may reveal encephalitis or small infarcts critical for targeted therapy.

5. Electroencephalographic Monitoring

EEG is essential for diagnosing nonconvulsive SE (NCSE) and guiding treatment titration in RSE/SRSE.

A. Indications:

  • Persistent altered mental status after convulsions.
  • Suspected NCSE or RSE.

B. Modalities:

  • Rapid (20-minute) EEG vs continuous EEG (cEEG).
  • Recommended 24–48 hours of cEEG in high-risk patients.

C. Key EEG patterns:

  • Periodic lateralized epileptiform discharges (PLEDs).
  • Rhythmic delta activity, epileptiform discharges >2.5 Hz (Salzburg criteria).

D. Therapeutic endpoints:

  • Electrographic seizure suppression or burst suppression to guide anesthetic infusions.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearl

cEEG uncovers seizures in ~15–20% of critically ill patients with unexplained encephalopathy; informs escalation and weaning of therapy.

6. Integrated Diagnostic Algorithm

A protocol-driven sequence ensures timely classification and management.

Integrated Diagnostic Algorithm for Status Epilepticus

1. Recognize SE
(Convulsions ≥5 min or recurrent w/o baseline recovery)
2. Stabilize and Treat
(ABCs + Benzodiazepine)
3. History & Exam
(Differentiate mimics, identify focal signs)
4. Parallel Labs
(Metabolic, tox, ASM levels, infection markers)
5. Neuroimaging
(Emergent CT → Deferred MRI as indicated)
6. EEG Monitoring
(Rapid EEG → cEEG as indicated)
7. Classify SE
(Standard SE → RSE → SRSE)
8. Communicate & Coordinate Care
(Neurology, Critical Care, Pharmacy, Nursing)
Figure 2: Integrated Diagnostic Algorithm for Status Epilepticus. This algorithm outlines key steps from initial recognition through classification and multidisciplinary team communication.

7. Pearls, Pitfalls, and Controversies

A. Clinical Pearls & Pitfalls:

  • Pearl: Under-recognition of NCSE delays treatment—cEEG is critical in patients with unexplained altered mental status after convulsive SE or in those at high risk.
  • Pitfall: Over-reliance on CT may miss encephalitis or small infarcts—pursue MRI when clinically indicated and safe to do so.
  • Pearl: Early and aggressive treatment of SE is associated with better outcomes; “time is brain.”
  • Pitfall: Inadequate dosing of initial benzodiazepines or second-line ASMs can lead to pseudo-refractoriness. Ensure weight-based, appropriate doses are administered.

B. Key Controversies and Evolving Definitions:

Controversy Icon A chat bubble with a question mark, indicating a point of controversy or debate. Evolving Definitions & Thresholds

The operational definition of SE (typically 5 minutes for generalized convulsive SE) continues to be discussed. Some debate whether a 10-minute threshold might be more appropriate for certain SE types or to avoid overtreatment, though current guidelines emphasize early intervention.

Controversy Icon A chat bubble with a question mark, indicating a point of controversy or debate. cEEG Resource Utilization

Continuous EEG (cEEG) is resource-intensive (equipment, personnel for interpretation). Balancing its high diagnostic yield in detecting NCSE and guiding therapy against these constraints is an ongoing challenge. Standardization of cEEG initiation criteria and minimum duration of monitoring are areas of active discussion and research.

Controversy Icon A chat bubble with a question mark, indicating a point of controversy or debate. Impact of cEEG on Long-Term Outcomes

While cEEG clearly improves detection of non-convulsive seizures and can guide acute therapy, robust evidence demonstrating a direct impact on long-term neurological outcomes or mortality is still evolving. Further research is needed to solidify its role in improving patient-centered long-term results beyond immediate seizure control.

References

  1. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515–1523.
  2. Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults. Epilepsy Currents. 2016;16(1):48–61.
  3. Brophy GM, Bell R, Claassen J, et al. Guidelines for the Evaluation and Management of Status Epilepticus. Neurocrit Care. 2012;17(1):123–134.
  4. Riviello JJ Jr, Ashwal S, Hirtz D, et al. Practice parameter: Diagnostic assessment of the child with status epilepticus. Neurology. 2006;67(9):1542–1550.
  5. Leitinger M, Beniczky S, Rohracher A, et al. Salzburg consensus criteria for non-convulsive status epilepticus. Epilepsy Behav. 2015;49:158–163.
  6. Rossetti AO, Schindler K, Sutter R, et al. Continuous vs routine electroencephalogram in critically ill adults with altered consciousness. JAMA Neurol. 2020;77(10):1225–1233.
  7. Claassen J, Hirsch LJ, Emerson RG, Bates JE, Thompson TB, Mayer SA. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology. 2001;57(6):1036–1042.
  8. Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498–1503.